Journal Francais D Ophtalmologie最新文献

{"title":"Spontaneous partial resolution of retinal detachment in a child with morning glory syndrome.","authors":"J-C Liu, S-J Zhang, X-M Yan, W-B Zhang","doi":"10.1016/j.jfo.2024.104362","DOIUrl":"https://doi.org/10.1016/j.jfo.2024.104362","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":" ","pages":"104362"},"PeriodicalIF":1.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Branch retinal vein occlusion and optic nerve retinal astrocytoma: Multimodal assessment.","authors":"F J Valentin-Bravo, R B El Jarroudi, X Valldeperas, L Broc Iturralde","doi":"10.1016/j.jfo.2024.104360","DOIUrl":"https://doi.org/10.1016/j.jfo.2024.104360","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":" ","pages":"104360"},"PeriodicalIF":1.2,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute macular neuroretinopathy in SARS-CoV-2 infection and the utility of the Spectralis® High Magnification Module HMM®.","authors":"E Pineda-Garrido, M A Pascual-Santiago, V Gómez-Calleja, A Miláns Del Bosch-De Linos, L López-Guajardo","doi":"10.1016/j.jfo.2024.104285","DOIUrl":"https://doi.org/10.1016/j.jfo.2024.104285","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":" ","pages":"104285"},"PeriodicalIF":1.2,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OCT peropératoire au cours de la chirurgie de la cataracte","authors":"R. Tahiri ,&nbsp;A. Miguel ,&nbsp;O. Moraru ,&nbsp;O. Sandali","doi":"10.1016/j.jfo.2024.104349","DOIUrl":"10.1016/j.jfo.2024.104349","url":null,"abstract":"<div><div>La tomographie par cohérence optique (OCT) peropératoire est un outil prometteur dans la chirurgie de la cataracte. Cet article explore les dispositifs disponibles et les applications pratiques de l’OCT peropératoire dans cette intervention chirurgicale. Il met en lumière les avantages potentiels de cette technologie, notamment dans l’évaluation des incisions, la détection des fragments résiduels et la confirmation des décollements de la membrane de Descemet. Malgré ses avantages, l’OCT peropératoire rencontre des défis pratiques tels que son coût et la nécessité d’une courbe d’apprentissage. Toutefois, son utilisation judicieuse pourrait contribuer à améliorer la qualité et la sécurité de la chirurgie de la cataracte.</div></div><div><div>Intraoperative Optical Coherence Tomography (OCT) is a promising tool in cataract surgery. This article explores available devices for intraoperative OCT and their practical applications in this surgical procedure. It highlights the potential benefits of this technology, particularly in evaluating incisions, detecting residual fragments, and confirming Descemet's membrane detachments. Despite its advantages, intraoperative OCT faces practical challenges, such as cost and the need for a learning curve. However, its judicious use could contribute to improving the quality and safety of cataract surgery.</div></div>","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 1","pages":"Article 104349"},"PeriodicalIF":1.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic microbiologique d’une infection de surface oculaire (hors virologie)","authors":"L. Baït-Merabet ,&nbsp;A. Kobal ,&nbsp;F. Brignole-Baudouin","doi":"10.1016/j.jfo.2024.104336","DOIUrl":"10.1016/j.jfo.2024.104336","url":null,"abstract":"<div><div>La surface oculaire est une structure exposée à de multiples agressions qui peuvent entraîner directement ou indirectement une contamination infectieuse et compromettre la fonction visuelle. Ce risque important justifie une prise en charge pluridisciplinaire, souvent dans un contexte d’urgence, unissant ophtalmologistes et microbiologistes, pour optimiser et orienter les investigations microbiologiques à réaliser sur des échantillons de faibles volumes, afin d’aboutir au meilleur traitement. Dans ce dossier, nous présentons les différentes étapes menant au diagnostic microbiologique, depuis les exigences préanalytiques, les méthodes de prélèvement, les conditions de transport, puis les étapes analytiques d’identification des pathogènes. Celles-ci sont basées sur l’examen direct au microscope associé aux techniques de culture, et d’identification par spectrométrie de masse et biologie moléculaire et enfin, l’évaluation de la sensibilité du potentiel pathogène vis-à-vis d’un panel d’anti-infectieux. Les méthodes de biologie moléculaire occupent désormais une place importante pour le diagnostic et la détection des gènes de résistance aux antibiotiques, elles améliorent le taux d’identification des micro-organismes, réduisent le temps nécessaire à l’obtention des résultats et améliorent ainsi la prise en charge thérapeutique. Néanmoins, l’examen microscopique et la culture microbiologique restent le « gold standard » dans le diagnostic de nombreuses infections oculaires.</div></div><div><div>The ocular surface is a structure exposed to multiple stresses that can directly or indirectly lead to infectious contamination and compromise visual function. This significant risk justifies multidisciplinary care, often in an emergency context, bringing together ophthalmologists and microbiologists to optimize and guide microbiological testing on small volume samples and ensure the most appropriate treatment. Herein, we present the various steps leading to microbiological diagnosis, from pre-analytical requirements, sampling methods, transport conditions, and then to the analytical steps of pathogen identification. These are based on microscopic examination associated with culture techniques, pathogen identification using mass spectrometry and molecular biology approaches and finally, antimicrobial susceptibility testing. Molecular biology methods have become important for the diagnosis and detection of antibiotic resistance genes, improving the identification rate of microorganisms, reducing the time needed to obtain results, and thus improving therapeutic management. Nevertheless, direct microbiological examination and culture remain the gold standards in the diagnosis of many ocular infections.</div></div>","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"47 10","pages":"Article 104336"},"PeriodicalIF":1.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 on uveal melanoma in France","authors":"A. Hamerstehl ,&nbsp;É. Gadiollet ,&nbsp;A. Martel ,&nbsp;A. Groulier ,&nbsp;D. Aloi ,&nbsp;A.M. Nguyen ,&nbsp;S. Lassalle ,&nbsp;C. Bertolotto ,&nbsp;J.-P. Caujolle ,&nbsp;C. Maschi ,&nbsp;A. Ducoulombier ,&nbsp;T. Mathis ,&nbsp;S. Baillif ,&nbsp;S. Nahon-Estève","doi":"10.1016/j.jfo.2024.104351","DOIUrl":"10.1016/j.jfo.2024.104351","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;Treatment delays due to the COVID-19 pandemic in uveal melanoma (UM) patients have led to an increased rate of enucleations in Europe. The impact of multiple COVID-19 lockdowns on UM management has not been assessed in France. The goal of this study was to assess whether delayed diagnosis could have led to more advanced stages and thus a higher rate of enucleations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Two datasets were analyzed: patients from two ocular oncology centers (dataset-1), with recording of sizes, prognostic stages (TNM) and treatments, and a national database (dataset-2), obtained by ICD-10 codes and medical procedures for clip placement. After year-by-year comparison, the pre-COVID-19 (2018–2019) and post-COVID-19 (2021–2022) periods were compared for each dataset. Five hundred and thirty-seven patients were diagnosed with UM (dataset-1), including 213 patients in the pre-COVID-19 period and 212 patients in the post-COVID-19 period. Similarly, 2187 patients were diagnosed with UM (dataset-2), of whom 914 patients and 864 patients were diagnosed in the pre-COVID-19 and post-COVID-19 periods, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A higher number of patients had locally advanced tumors during the post-COVID-19 period compared to the pre-COVID-19 period (cT1&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;66, cT2&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;64, cT3&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;66 and cT4&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;21 vs. cT1&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;59, cT2&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;82, cT3&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;65 and cT4&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;7, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.03), but without difference in ciliary body involvement, extraocular extension or AJCC stage (dataset-1). Treatments were similar between the pre-COVID-19 and post-COVID-19 periods in dataset-1 (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.36) and dataset-2 (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.47), with a higher ratio of proton beam therapy to primary enucleation in 2020 than in the pre-COVID-19 and post-COVID-19 periods (21.4 vs. 8.6 and 6.3, &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.02).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The COVID-19 pandemic did not impact the ophthalmological management of UM patients in France, but more locally advanced stages were observed upon initial presentation during the post-COVID-19 period.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectifs&lt;/h3&gt;&lt;div&gt;Les retards de traitement dus au COVID-19 chez les patients atteints de mélanome uvéal (MU) ont entraîné une augmentation du taux d’énucléations en Europe. L’impact des multiples confinements liés au COVID-19 sur la prise en charge du MU n’a pas été évalué en France. Le but de cette étude était d’évaluer si des diagnostics tardifs ont pu conduire à des stades plus avancés et donc à un taux d’énucléations plus élevé.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Deux ensembles de données ont été analysés : les patients de deux centres d’oncologie oculaire (données-1), avec la collecte des tailles, de stades pronostiques (TNM) et des traitements, et une base ","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 1","pages":"Article 104351"},"PeriodicalIF":1.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluocinolone acetonide implant (FAci) one month after dexamethasone implant (DEXi) for chronic diabetic macular edema: 1-year results","authors":"Q. Lampin,&nbsp;J. Poret,&nbsp;M. Gherras,&nbsp;B. Jany,&nbsp;T.H.C. Tran","doi":"10.1016/j.jfo.2024.104352","DOIUrl":"10.1016/j.jfo.2024.104352","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;To evaluate the safety and efficacy of FACi injected 1&lt;!--&gt; &lt;!--&gt;month after the last DEXi injection in pseudophakic patients without ocular hypertension who required frequent DEXi injections (&lt;&lt;!--&gt; &lt;!--&gt;6&lt;!--&gt; &lt;!--&gt;months).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patients and methods&lt;/h3&gt;&lt;div&gt;This was a prospective study including pseudophakic patients with chronic diabetic macular edema (DME) previously treated with DEXi without secondary ocular hypertension. All patients received DEXi followed by FAci one month later. Visits were scheduled at baseline, M1, then every 3&lt;!--&gt; &lt;!--&gt;months up to 12&lt;!--&gt; &lt;!--&gt;months.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Fourteen eyes of 11 patients were included and were followed until the 12-month time point. Visual gain was significant at M6 (+5.6 letters) and at M9 (+7.1 letters). A reduction in central macular thickness was obtained at 1 month (−86&lt;!--&gt; &lt;!--&gt;μm), remaining stable over subsequent visits. The rate of ocular hypertension requiring pressure lowering treatment was 14%. Three eyes needed additional treatment (21%); one eye was treated with aflibercept, and 2 eyes with DEXi at M5 and M11. No patient underwant additional FAc implantation during the 11 months of follow-up.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Injection of FAci one month after DEXi in pseudophakic patients with chronic DME who responded previously to DEXi results in anatomical improvement and deferred visual gain. This prospective study demonstrates the efficacy and safety of both implants in DME patients who have been previously treated with other therapies.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Évaluer l’efficacité et la tolérance de l’implant intravitréen d’acétonide de fluocinolone (FAci) injecté 1 mois après la dernière injection de dexaméthasone (DEXi) chez des patients pseudophaques ayant nécessité des injections fréquentes de DEXi (&lt;&lt;!--&gt; &lt;!--&gt;6 mois) sans hypertension oculaire.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patients et méthode&lt;/h3&gt;&lt;div&gt;Il s’agit d’une étude prospective incluant des patients pseudophaques souffrant d’un œdème maculaire diabétique (OMD) chronique précédemment traité par DEXi sans hypertension oculaire. Tous les patients ont reçu du DEXi puis du FAci un mois plus tard. Les visites ont été programmées au début de l’étude, à M1, puis tous les 3 mois jusqu’à 12 mois.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Quatorze yeux de 11 patients ont été inclus et ont été suivis jusqu’à 12 mois. Le gain visuel était significatif à M6 (+5,6 lettres) et à M9 (+7,1 lettres). Une réduction de l’épaisseur maculaire centrale a été obtenue à 1 mois (−86&lt;!--&gt; &lt;!--&gt;μm) puis est restée stable au fil des visites. Le taux d’hypertension oculaire nécessitant un traitement hypotonisant intraoculaire était de 14 %. Trois yeux ont nécessité un traitement supplémentaire (21 %) : un œil a été traité par aflibercept et 2 yeux par DEXi à M5 et M11. Aucun patient n’a eu de retraitement de l’implant Fac au cours des 11 mois de l’étude.&lt;/div&gt;&lt;/div","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 1","pages":"Article 104352"},"PeriodicalIF":1.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rétinites virales","authors":"S. Touhami ,&nbsp;A. Toutée ,&nbsp;Y.-R. Chung ,&nbsp;V. Touitou ,&nbsp;B. Bodaghi","doi":"10.1016/j.jfo.2024.104341","DOIUrl":"10.1016/j.jfo.2024.104341","url":null,"abstract":"<div><div>Les virus du groupe herpès, tels que l’HSV (herpès simplex virus) 1 et 2, le VZV (varicella zoster virus) et le CMV (cytomégalovirus) peuvent provoquer des rétinites nécrosantes susceptibles de causer la cécité. Ces nécroses rétiniennes virales (NRV) se manifestent généralement sous trois formes suivant l’état immunitaire du patient: la nécrose rétinienne aiguë (ARN), la nécrose rétinienne externe progressive (PORN) et la rétinite à CMV. Bien que des traitements médicamenteux spécifiques et efficaces soient disponibles aujourd’hui, la précocité de l’instauration des traitements est essentielle pour améliorer le pronostic.</div></div><div><div>Viruses belonging to the herpes family group, including HSV (herpes simplex virus) 1 and 2, VZV (varicella zoster virus) and CMV (cytomegalovirus) are the leading causes of necrotizing retinitis. These viral retinal necroses generally manifest in three forms, depending on the patient's immune status: acute retinal necrosis (ARN), progressive outer retinal necrosis (PORN) and CMV retinitis. Although specific, effective drug treatments are available today, early treatment initiation is essential to avoid sight-threatening complications.</div></div>","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"47 10","pages":"Article 104341"},"PeriodicalIF":1.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infections en ophtalmologie : actualités et perspectives 2024","authors":"B. Bodaghi ,&nbsp;T. Bourcier ,&nbsp;M. Labetoulle","doi":"10.1016/j.jfo.2024.104343","DOIUrl":"10.1016/j.jfo.2024.104343","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"47 10","pages":"Article 104343"},"PeriodicalIF":1.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors predictive of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity","authors":"N. Sahinoglu-Keskek ,&nbsp;I. Akkoyun ,&nbsp;B. Torer ,&nbsp;B. Cetinkaya ,&nbsp;H. Gülcan ,&nbsp;G. Yilmaz ,&nbsp;S. Oto","doi":"10.1016/j.jfo.2024.104348","DOIUrl":"10.1016/j.jfo.2024.104348","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;Anti-VEGF agents are used in the treatment of aggressive retinopathy of prematurity (A-ROP), which is a rapidly progressive form of retinopathy of prematurity (ROP). This study aimed to evaluate risk factors for the early reactivation after anti-VEGF therapy with intravitreal ranibizumab (IVR) injection.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Consecutive cases of A-ROP were included in this retrospective study. Intravitreal ranibizumab (0.25&lt;!--&gt; &lt;!--&gt;mg, Lucentis, Novartis AG) was injected in all A-ROP cases as initial therapy. Probable risk factors were reviewed. A reactivation in 4 weeks or less was defined as “early”, and greater than 4 weeks was defined as “late”. Since reactivations were observed in Zone II in all cases, laser photocoagulation (LP) was performed as rescue therapy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The study consisted of 16 patients with A-ROP, all of whom experienced reactivation. In 6 cases,reactivation was seen early (Group-E), and in 10 cases, reactivation was late (Group-L). The mean gestational age of Group-E and Group-L were 26.60 (±&lt;!--&gt; &lt;!--&gt;0.89) and 26.73 (±&lt;!--&gt; &lt;!--&gt;2.10) weeks respectively (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.9), and mean birth weights were 918 (±&lt;!--&gt; &lt;!--&gt;282) and 898 (±&lt;!--&gt; &lt;!--&gt;0188) grams respectively (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.8). Zone I ROP was seen at a higher rate in Group-E (83.3%) than Group-L (30%) (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.009). Total O&lt;sub&gt;2&lt;/sub&gt; treatment duration in Group-E was statistically significantly longer than Group-L (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.03). The mean value of platelet distribution width (PDW) in Group-E was statistically significantly higher (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.002).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;In patients with A-ROP, extended duration of O&lt;sub&gt;2&lt;/sub&gt; therapy and high values of PDW might be factors predictive of early reactivation after intravitreal ranibizumab injection.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Les agents anti-VEGF sont utilisés dans le traitement de la rétinopathie agressive du prématuré (A-ROP) qui est une forme rapidement progressive de la rétinopathie du prématuré (ROP). Cette étude visait à évaluer les facteurs de risque ayant un effet sur la réactivation précoce après l’injection intravitréenne de ranibizumab (IVR) en tant que thérapie anti-VEGF.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Les cas consécutifs d’A-ROP ont été inclus dans cette étude rétrospective. Le ranibizumab intravitréen (0,25&lt;!--&gt; &lt;!--&gt;mg, Lucentis, Novartis AG) a été injecté dans tous les cas de POA comme traitement initial. Les facteurs de risque probables ont été examinés. Une réactivation en 4 semaines ou moins a été considérée comme « précoce » et une réactivation en plus de 4 semaines a été considérée comme « tardive ». Étant donné que des réactivations ont été observées dans la zone II dans tous les cas, une photocoagulation au laser (LP) a été effectuée comme traitement de secours.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résulta","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 1","pages":"Article 104348"},"PeriodicalIF":1.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}